CBD blocks THC's psychosis-like effects in the brain by reversing a specific molecular signaling pathway
In rats, THC in the hippocampus caused psychosis-like dopamine dysregulation and amplified emotional salience, while CBD co-administration reversed these effects by downregulating ERK1-2 phosphorylation, identifying a specific molecular mechanism.
Quick Facts
What This Study Found
Intra-hippocampal THC increased VTA dopamine neuron firing and bursting, decreased GABA frequency, and amplified oscillatory activity via ERK1-2 phosphorylation. THC also potentiated emotional salience in behavioral tests. CBD co-administration reversed all changes by downregulating pERK1-2, and pharmacological reactivation of pERK1-2 blocked CBD's protective effects.
Key Numbers
THC increased VTA DA frequency and bursting, decreased GABA frequency, amplified beta/gamma/epsilon oscillations. All effects reversed by CBD co-administration. Mechanism: THC upregulates pERK1-2; CBD downregulates it. Pharmacological ERK reactivation blocked CBD's protective effect.
How They Did This
In vivo electrophysiology in male Sprague Dawley rats with intra-hippocampal drug delivery. Measured VTA dopamine and GABA neuron activity, oscillatory magnitudes, and pERK1-2 levels. Behavioral tests included morphine place preference and fear conditioning assays.
Why This Research Matters
This identifies the first specific molecular mechanism by which CBD counteracts THC's psychosis-like effects: ERK1-2 phosphorylation in the hippocampus. This could explain why high-THC/low-CBD strains are associated with greater psychosis risk and inform both strain recommendations and drug development.
The Bigger Picture
The epidemiological finding that high-THC/low-CBD cannabis increases psychosis risk now has a molecular explanation. ERK signaling in the hippocampus is the nexus where THC and CBD exert opposing effects on the dopamine system, providing a drug development target.
What This Study Doesn't Tell Us
Rat model with direct hippocampal injection, not oral or inhaled cannabinoid administration. Acute effects only. Male rats only. The translation from this specific mechanism to human psychosis risk is assumed but not demonstrated.
Questions This Raises
- ?Would CBD doses achievable through normal consumption be sufficient to block THC's ERK effects?
- ?Could ERK1-2 inhibitors serve as antipsychotics?
- ?Does this mechanism explain individual differences in THC sensitivity?
Trust & Context
- Key Stat:
- CBD reversed all of THC's psychosis-like brain effects by blocking ERK1-2 phosphorylation
- Evidence Grade:
- Preliminary: rigorous mechanistic animal study with multiple converging measures, published in Journal of Neuroscience.
- Study Age:
- Published in 2019 in The Journal of Neuroscience.
- Original Title:
- Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
- Published In:
- The Journal of neuroscience : the official journal of the Society for Neuroscience, 39(44), 8762-8777 (2019)
- Authors:
- Hudson, Roger(4), Renard, Justine(6), Norris, Christopher, Rushlow, Walter J, Laviolette, Steven R
- Database ID:
- RTHC-02078
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How does CBD protect against THC's psychosis effects?
This study found THC activates ERK1-2 signaling in the hippocampus, which dysregulates dopamine neurons and amplifies emotional responses. CBD reverses this by blocking ERK1-2 phosphorylation. When researchers re-activated ERK signaling, CBD's protection disappeared.
Why does cannabis strain matter for mental health?
High-THC strains activate ERK1-2 in the hippocampus, disrupting dopamine regulation in ways that resemble psychosis. CBD in balanced strains counteracts this specific pathway, potentially explaining why high-THC/low-CBD strains carry greater psychiatric risk.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02078APA
Hudson, Roger; Renard, Justine; Norris, Christopher; Rushlow, Walter J; Laviolette, Steven R. (2019). Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.. The Journal of neuroscience : the official journal of the Society for Neuroscience, 39(44), 8762-8777. https://doi.org/10.1523/JNEUROSCI.0708-19.2019
MLA
Hudson, Roger, et al. "Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.." The Journal of neuroscience : the official journal of the Society for Neuroscience, 2019. https://doi.org/10.1523/JNEUROSCI.0708-19.2019
RethinkTHC
RethinkTHC Research Database. "Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9..." RTHC-02078. Retrieved from https://rethinkthc.com/research/hudson-2019-cannabidiol-counteracts-the-psychotropic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.